http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9062876&dopt=Abstract
Serum alanine aminotransferase level in relation to hepatitis
B and C virus infections among blood donors.
Tsai JF, Jeng JE, Ho MS, Wang CS, Chang WY, Hsieh MY, Lin ZY, Tsai JH.
Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of
China.
To assess the serum alanine aminotransferase (ALT) activity in relation to
hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among blood
donors, antibodies to HCV (anti-HCV) and hepatitis B surface antigen (HBsAg)
were detected in 400 blood donors with normal ALT level (< or = 750 mumol/s per
liter), and 76 blood donors with raised ALT level. The prevalence of anti-HCV
(10.5%) and HBsAg (28.9%) in the latter was higher than that (2.0% and 17.5%,
respectively) in the former (p < 0.001 and p < 0.03, respectively). There was a
trend that indicated that the risk of anti-HCV positivity increased with
increasing age (p < 0.001). Thirty of 76 (39.5%) donors with raised ALT level
were positive for anti-HCV or HBsAg. Compared with HBsAg-positive donors, donors
with anti-HCV had higher serum ALT levels (p < 0.01) and greater mean age (p <
0.01). Multivariate analysis indicated that both anti-HCV (odds ratio: 6.2; 95%
confidence interval: 2.2-17.8) and HBsAg (odds ratio: 2.2; 95% confidence
interval: 1.3-3.9) were significantly associated with raised serum ALT activity.
The estimated population-attributable risk was 8.6% for anti-HCV, and 13.8% for
HBsAg. In conclusion, although HBV and
HCV
infections are independent risk factors of raised ALT activity among blood
donors, they play a minor role in the etiology of raised ALT activity.
PMID: 9062876 [PubMed - indexed for MEDLINE]
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.